title: HLA expression in hepatocellular carcinoma cell lines.
abstract: The present study undertook to investigate the biological significance of human leucocyte antigen expression in hepatocellular carcinoma and to elucidate the role of potential modulating agents on human leucocyte antigen expression. These studies used several hepatic tumour-derived cell lines as in vitro model systems. The cell lines included PLC/PRF/5 (Alexander cell line), Hep3B, HepG2, TONG PHC, HA22T/VGH, HA59T/VGH and Mahlavu. The cell lines K562 and Raji were used as negative and positive controls, respectively. K562, a B lymphoid-derived cell line, was shown to express negligible amounts of human leucocyte antigens, while Raji, an erythromyeloid-derived cell line, expressed both class I and class II human leucocyte antigens as well as their respective invariant chains, beta 2-microglobulin and Ii. Using an ELISA, experiments performed on these cell lines confirmed the natural expression of class I and class II antigens by the HA22T/VGH and HA59T/VGH cell lines, whereas PLC/PRF/5 displayed class II surface antigens only. The effects of modulating agents such as interferon-gamma sodium butyrate and clofazimine on human leucocyte antigen expression were investigated using the HA22T/VGH, HA59T/VGH and TONG PHC cell lines. These agents increased class II and class II human leucocyte antigen expression on HA22T/VGH and TONG PHC cells, but had no effect on the HA59T/VGH cell line. The results suggest a potential use for these agents as modulators of human leucocyte antigen expression by human heptocellular cell lines.
authors.affiliation: Department of Immunology, School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.
authors.forename: A A
authors.initials: AA
authors.lastname: Wadee
authors.forename: A
authors.initials: A
authors.lastname: Paterson
authors.forename: K A
authors.initials: KA
authors.lastname: Coplan
authors.forename: S G
authors.initials: SG
authors.lastname: Reddy
mesh_terms: D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D006528:Carcinoma, Hepatocellular / Q000276:immunology*; D002991:Clofazimine / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D006680:HLA Antigens / Q000096:biosynthesis* / Q000276:immunology; D006681:HLA-D Antigens / Q000096:biosynthesis; D000949:Histocompatibility Antigens Class II / Q000096:biosynthesis; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D008113:Liver Neoplasms / Q000276:immunology*; D014407:Tumor Cells, Cultured / Q000276:immunology
chemical_list: D002087:Butyrates; D006680:HLA Antigens; D006681:HLA-D Antigens; D000949:Histocompatibility Antigens Class II; D020148:Butyric Acid; D007371:Interferon-gamma; D002991:Clofazimine